ClinicalTrials.gg
Drug

AZD5305 clinical trials

Also written Saruparib and AZD5305.

studies test it
16
open now
9
in phase 3
4
first study started
2019

How each study uses AZD5305 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the AZD5305 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Saruparib (AZD5305)
3

Development codes

AZD5305
7

Other names

Saruparib
9

Studies by the year they started

16 studies that test it; most in 2025 (4)

Studies that test AZD5305, by start year
YearStudies
20191
20201
20212
20222
20232
20241
20254
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
10
Phase 2
6
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 3

AstraZeneca (13) · Abramson Cancer Center at Penn Medicine (1) · OHSU Knight Cancer Institute (1) · University of Leeds (1)

Often tested with

Tested in the same studies.

Olaparib (2) · Furosemide (1) · Apalutamide (1) · Darolutamide (1) · AZD9833 (1) · Letrozole (1) · Polymerase Theta Helicase Inhibitor AZD4956 (1) · Puxitatug samrotecan (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test AZD5305, phase 3 first.

Studies

Open first, then newest update. How each study uses AZD5305 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Given beside what is tested · 3 — AZD5305 is usual care or a partner of the new treatment

Codes

What other systems call AZD5305 · ClinicalTrials.gg INT001893

  • MeSH (NLM) C000722772AZD5305One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.